Geraldine Teppaz - Publications

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 02, 2026

CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.

Journal: Science advances

Published: November 18, 2022

First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 25, 2022

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.

Journal: Science advances

Published: June 03, 2020

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

Journal: The Journal of clinical investigation

Published: December 06, 2019

SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: November 22, 2018

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: January 05, 2016

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Journal: mAbs

Published: July 30, 2014

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Journal: International journal of cancer

Published: October 31, 2012